SCHEMBL3272074

SCHEMBL3272074

CC(C)(C)[Si](C)(C)OCCCCCCI

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5856290 1.00 DUT (0.37) DUT
SCHEMBL17760869 1.00 DUT (0.37) DUT
SCHEMBL3272116 1.00 DUT (0.37) DUT
SCHEMBL345800 0.98 DUT (0.38) DUT
SCHEMBL432514 0.91 DUT (0.39) DUT
SCHEMBL9007756 0.89 DUT (0.42) DUT
SCHEMBL27241092 0.89 DUT (0.42) DUT
SCHEMBL14245094 0.89 DUT (0.42) DUT
SCHEMBL8063404 0.86 DUT (0.43) DUT
SCHEMBL25378318 0.83 DUT (0.36) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130302247-A1 SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2013-11-14 US disclosed
US-20130302247-A1 SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2013-11-14 US disclosed
US-7931946-B2 Liquid crystal compound containing sulfone group, liquid crystal composition comprising the same, and optical film using the same liquid crystal composition LG CHEM, LTD. (KR) 2011-04-26 US disclosed
US-20100096590-A1 NOVEL LIQUID CRYSTAL COMPOUND CONTAINING SULFONE GROUP, LIQUID CRYSTAL COMPOSITION COMPRISING THE SAME, AND OPTICAL FILM USING THE SAME LIQUID CRYSTAL COMPOSITION LG CHEM, LTD. (KR) 2010-04-22 US disclosed
US-7691836-B2 Progesterone receptor modulators N.V. ORGANON (NL) 2010-04-06 US disclosed
EP-1735330-B1 PROGESTERONE RECEPTOR MODULATORS ORGANON NV (NL) 2007-11-28 EP disclosed
US-20070203105-A1 Progesterone Receptor Modulators N.V. ORGANON (NL) 2007-08-30 US disclosed
US-5401732-A Autoimmune diseases LEO PHARMACEUTICAL PRODUCTS LTD. A/S KEMISKE FABRIK PRODUKIONSAKTIESE SKAB (DK) 1995-03-28 US disclosed
EP-0460032-B1 NOVEL VITAMIN D ANALOGUES LEO PHARM PROD LTD (DK) 1994-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203105-A1 Progesterone Receptor Modulators PGR, PGRMC1, PGRMC2 DUT 1885/4885
US-20100096590-A1 NOVEL LIQUID CRYSTAL COMPOUND CONTAINING SULFONE GROUP, LIQUID CRYSTAL COMPOSITION COMPRISING THE SAME, AND OPTICAL FILM USING THE SAME LIQUID CRYSTAL COMPOSITION SFXN1, SOST, SFXN3 DUT 4659/4885
US-20130302247-A1 SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF ALOX15B, ALOX15, ALOX5 DUT 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.